報價延遲最少15分鐘:2025/05/31 19:54 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
28.95 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.18/1.12
|
|
企業價值
5.68B
|
| 資產負債 |
|
每股賬面淨值
5.53
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
627.24M
|
|
每股收益
0.89
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/05/31 19:54 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue. |